Diseases that cause stenosis of the responsible bronchus
Conditions
Interventions
For 5 days from 4-8 hours after the day of bronchoscopy: potassium clavulanate amoxicillin hydrate 3 for 3, amoxicillin hydrate 3 for 3 orally
if there is moderate renal impairment (eGFR 10-49 mL/min), dose reduced to 2 for 2 tablets each
D000900
antibiotics
Sponsors
Nishioka Yasuhiko
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients aged 20 years or older at the time of consent (regardless of gender) 2) Patients with bronchoscopy showing stenosis in the bronchi up to the subareolar bronchus (excluding postoperative changes or physiologic stenosis) 3) Patients who are able to make an outpatient visit to the site after 4 weeks 4) Patients who have been fully informed about their participation in this study, and who have given written consent to participate in the study of their own free will after full understanding of the study
Exclusion criteria
Exclusion criteria: 1) Patients with a history of allergy to penicillin or cephem antibiotics 2) Patients with a history of jaundice or hepatic dysfunction with penicillin antibacterial agents 3) Patients with severe renal dysfunction (eGFR < 10 mL/min) 4) Patients with a body temperature of 37 degrees or higher (axillary temperature) prior to bronchoscopy 5) Patients with a clear active infection prior to bronchoscopy 6) Patients who have received antimicrobial therapy within 1 week of bronchoscopy 7) Patients who are participating or intend to participate in other clinical studies while participating in this study 8) Participation in the research is not in the best interest of the research subject or is deemed to interfere with the evaluation specific to the clinical research protocol 9) Any employee of the Principal Investigator or the site who is directly involved in this or other clinical research, or any family member of such an employee or Principal Investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients who developed respiratory infections that required antibiotic treatment within 4 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Proportion of cases requiring a change in lung cancer treatment (postponement, discontinuation, or death) after 28 days of bronchoscopy 2)Proportion of patients who developed respiratory infection after bronchoscopy in the group that received prophylactic antibiotics and the group that did not receive prophylactic antibiotics as scheduled 3)Proportion of respiratory infections after bronchoscopy by degree of stenosis (26-50%, 51-75%, 76-100%) 4)Percentage of patients who received antibiotics due to other factors within 4 weeks of examination and percentage of patients who developed respiratory infections after bronchoscopy when those patients are excluded 5)Number of adverse events due to antibiotics, incidence rate, and nature and severity of such events | — |
Contacts
Public ContactMiyamoto Kenya
Tokushima University Hospital
Outcome results
None listed